FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(11mit of 1y	pe response	·3)															
1. Name and Address of Reporting Person * Cheong Kwang Soo				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]							[RNN	1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455				3. Date of Earliest Transaction (Month/Day/Year) 06/09/2016							r)		Officer (give	title below)		(specify below)	
(Street) ROCKVILLE, MD 20850				4. If Amendment, Date Original Filed(Month/Day/Year)							(ear)	_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(Cit	(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							Acquired	red, Disposed of, or Beneficially Owned				
1.Title of S (Instr. 3)	1.Title of Security 2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Date, any (Month/Day/Ye.		Date, if C	(Instr. 8)		(A) (In:	4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5) (A) or Amount (D)		of (D) Own Trai	Owned Following Reported Transaction(s) (Instr. 3 and 4)		I C	Ownership of orm: B Orect (D) Or Indirect (I	eneficial wnership	
			Table II -					in t dis uired, D	his fo plays pisposo	orm ar a cur	e not re rently v	equired to valid OME ficially Ow	respond control r	unless the	tion contain e form	ou ble 14	. (5 02)
	I_				ts, c	alls, warr										. I	I
	Conversion			Transaction Code (Instr. 8)				Expirat	ion Da	xercisable and n Date Jay/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect	
				Code	V	(A)	(D)	Date Exercis	able	Expir Date	ation	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 0.28	06/09/2016		A		225,000		06/09/	2017	06/0	9/2026	Common Stock	225,000	\$ 0	225,000	D	

Reporting Owners

Donastina Commun Name / Addison	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Cheong Kwang Soo C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X					

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Kwang Soo Cheong	06/10/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.